Beta-Blocker and Calcium Channel Blocker Toxicity: Management

Intoxications with beta-blockers and calcium channel blockers are among the most dangerous cardiovascular poisonings in emergency medicine. Both drug classes are among the most commonly prescribed antihypertensives worldwide – and this widespread availability explains why they regularly play a role in suicidal ingestion, accidental overdose, and drug interactions. The combination of treatment-refractory bradycardia, severe hypotension, and cardiogenic shock can rapidly lead to cardiac arrest. Understanding the pathophysiological differences between both substance groups and the consistent application of an evidence-based stepwise therapy are crucial for outcome. This article examines the pharmacological fundamentals, clinical presentation, and most importantly the structured management including high-dose insulin euglycemia therapy (HIET), lipid emulsion infusion, and differentiated catecholamine use.

Pharmacological Fundamentals and Pathophysiology

Beta-Blockers

Beta-blockers competitively antagonize β₁- and partially β₂-adrenergic receptors on the heart and vascular smooth muscle. At therapeutic doses, they reduce heart rate, contractility, and AV conduction. In overdose, these effects are drastically potentiated:

• Negative chronotropy: Sinus bradycardia progressing to asystole
• Negative inotropy: Reduction in cardiac output, cardiogenic shock
• Negative dromotropy: AV blocks up to third degree
• Membrane stabilization: Some beta-blockers (especially propranolol, sotalol) possess sodium channel-blocking properties that lead to QRS widening and ventricular arrhythmias

Additionally, beta-blockers inhibit hepatic glycogenolysis and can cause severe hypoglycemia – a frequently underestimated effect that is particularly relevant in children and diabetic patients.

Particularly toxic agents:

• Propranolol: High lipophilicity, CNS penetration (seizures), sodium channel blockade
• Sotalol: Additional class III antiarrhythmic effect (QT prolongation, Torsades de Pointes)
• Carvedilol: Combined α₁- and β-blockade, pronounced vasodilation

Calcium Channel Blockers

Calcium channel blockers (CCBs) inhibit voltage-dependent L-type calcium channels. Two therapeutically relevant groups with different toxicity profiles are distinguished:

• Dihydropyridines (amlodipine, nifedipine, lercanidipine): Primarily vascular effect; in overdose, pronounced vasodilation with distributive shock. Reflex tachycardia may initially be present but is lost in massive intoxication.
• Non-dihydropyridines (verapamil, diltiazem): Primarily cardiac effect; severe bradycardia and cardiodepression predominate. Verapamil intoxications are considered particularly life-threatening.

The central metabolic consequence of CCB poisoning is the inhibition of insulin-mediated glucose uptake into cardiomyocytes. The beta cells of the pancreas require calcium influx for insulin secretion – CCB blockade creates a relative insulin deficiency. The heart, which increasingly relies on glucose as an energy substrate in stress situations, enters a metabolic crisis. This concept forms the rationale for high-dose insulin therapy.

Common Final Pathway

Despite different mechanisms, both types of intoxication converge on a common final pathway:

1. Bradycardia and conduction disturbances
2. Myocardial depression with reduced cardiac output
3. Hypotension and organ hypoperfusion
4. Metabolic acidosis, rising lactate levels
5. Multi-organ failure and cardiac arrest

Clinical Presentation and Diagnostics

Symptom development depends on the substance, dose, pharmaceutical formulation (extended-release preparations!), and co-medications. Extended-release formulations can cause delayed symptom progression over hours – therefore, an all-clear after a short observation period is not justified.

Key Symptoms

Parameter	Beta-Blocker Intoxication	CCB Intoxication
Heart rate	Bradycardia	Bradycardia (non-DHP), initially possible tachycardia (DHP)
Blood pressure	Hypotension	Severe hypotension
ECG	AV block, QRS widening (propranolol), QT prolongation (sotalol)	AV block, junctional rhythm
Blood glucose	Hypoglycemia	Hyperglycemia (inhibition of insulin secretion)
CNS	Somnolence, seizures (propranolol)	Altered mental status
Other	Bronchospasm	Paralytic ileus, pulmonary edema

Diagnostic Measures

• 12-lead ECG: Rhythm analysis, QRS duration, QTc interval
• Continuous monitoring: SpO₂, invasive blood pressure monitoring, extended hemodynamic monitoring if available
• Laboratory diagnostics: ABG (acidosis, lactate), blood glucose (frequent checks!), electrolytes (potassium, calcium, magnesium), renal and hepatic function
• Echocardiography: Assessment of myocardial pump function, volume status
• Drug levels: If available, possible for some substances, but do not delay therapeutic decisions

Stepwise Management of Intoxication

Therapy follows an escalating stepwise approach. The sequence is guided by severity and hemodynamic response. The key principle is: Do not wait for one measure to fail – escalate early and in parallel.

Step 1: Basic Measures

Gastrointestinal Decontamination:

• Activated charcoal (1 g/kg body weight, max. 50 g) if ingestion occurred within the last 1–2 hours and the airway is secured
• For extended-release preparations: Consider repeated-dose activated charcoal
• Gastric lavage only in exceptional cases with very recent, potentially lethal ingestion
• Whole bowel irrigation with polyethylene glycol for extended-release preparations and ingestion of large quantities

Volume Resuscitation:

• Crystalloid boluses (250–500 mL, repeatable) for preload optimization
• Caution: Excessive volume administration with already compromised pump function can aggravate pulmonary edema. Echocardiography-guided volume administration is desirable.

Atropine:

• 0.5–1 mg IV, repeatable up to 3 mg total dose
• In beta-blocker and CCB intoxications, often ineffective since the bradycardia is not vagally mediated
• Nevertheless justified as a first-line measure, as it is rapidly available and has few side effects

Step 2: Calcium

Calcium administration is particularly pathophysiologically rational in CCB intoxications, as it partially overcomes the competitive inhibition at the L-type channel. In beta-blocker poisoning, the benefit is less, but it is still indicated in combined intoxications.

• Calcium chloride 10%: 20 mL (approx. 13.6 mEq Ca²⁺) IV over 5–10 min, or
• Calcium gluconate 10%: 60 mL (equivalent to approx. 13.6 mEq Ca²⁺) IV over 5–10 min
• Repeat every 15–20 minutes, up to 3–4 boluses
• Subsequently calcium infusion: 0.2–0.4 mEq/kg/h
• Target serum calcium: Up to twice the upper limit of normal (monitor ionized Ca²⁺ frequently)
• Caution: Calcium chloride must be administered via a central venous access (tissue necrosis with extravasation). Calcium gluconate is better tolerated peripherally.

Step 3: High-Dose Insulin Euglycemia Therapy (HIET)

HIET is considered the cornerstone of therapy for hemodynamically significant CCB and beta-blocker intoxications according to current expert opinion and toxicology guidelines. Its mechanism of action extends far beyond glucose metabolism:

• Positive inotropy: Insulin promotes glucose uptake and aerobic metabolism in cardiomyocytes independent of the calcium channel
• Coronary artery vasodilation: Improvement of myocardial perfusion
• Anti-inflammatory and anti-apoptotic: Cytoprotective effects

Dosing Protocol:

1. Bolus: Insulin (human insulin or insulin analog) 1 IU/kg body weight IV
2. Infusion: Start at 1 IU/kg/h, titrate up to 10 IU/kg/h if hemodynamic improvement is absent
3. Glucose supplementation: Concurrent dextrose bolus (0.5 g/kg) and infusion (10–20% glucose) to prevent hypoglycemia
4. Blood glucose monitoring: Every 15–30 minutes during the initial phase, then hourly
5. Potassium monitoring: Insulin lowers serum potassium – supplement as needed (target: K⁺ > 3.0 mmol/L)

Practical Tips for HIET:

• Onset of action may take 15–60 minutes – do not give up too early
• Hemodynamic improvement often appears before heart rate increases
• Failure of blood glucose to decrease despite high insulin doses suggests a severe metabolic crisis and underscores the need for dose escalation
• In practice, the most common errors are underdosing and delayed initiation

Step 4: Catecholamines and Vasopressors

For persistent hypotension despite volume, calcium, and HIET, catecholamines are indicated. The selection depends on the predominant hemodynamic problem:

For predominantly cardiogenic shock (reduced contractility):

• Norepinephrine: 0.1–3 µg/kg/min as first-line vasopressor
• Epinephrine: 0.1–1 µg/kg/min for concurrent bradycardia and hypotension. Particularly useful in beta-blocker intoxications as it competes at the β-receptor
• Dobutamine: 5–20 µg/kg/min for inotropic support (caution: may be ineffective with complete β-receptor blockade)

For predominantly distributive shock (vasodilation in DHP intoxication):

• Norepinephrine or vasopressin (0.01–0.04 IU/min): Vasopressin acts via V₁ receptors independently of the adrenergic system and can be effective in catecholamine-refractory shock

Important: In severe beta-blocker intoxication, massive catecholamine resistance may exist. Doses far exceeding the usual range may be required. Titrate based on hemodynamic effect.

Step 5: Lipid Emulsion Infusion (Intravenous Lipid Emulsion – ILE)

Intravenous lipid emulsion (Intralipid® 20%) was originally established for local anesthetic toxicity but is now also used for lipophilic beta-blocker and CCB intoxications based on current evidence.

Hypothetical Mechanisms of Action:

• Lipid sink theory: Lipid droplets bind lipophilic substances and reduce free plasma concentration
• Direct cardiac effects: Fatty acids as an alternative energy substrate for the myocardium
• Increase in intravascular volume

Dosing:

• Bolus: 1.5 mL/kg body weight Intralipid® 20% over 2–3 minutes
• Infusion: 0.25 mL/kg/min over 30–60 minutes
• Maximum dose: 10–12 mL/kg body weight within the first hour
• If response is inadequate: Repeat bolus once

Limitations:

• The level of evidence is based predominantly on case reports and animal studies
• ILE can interfere with laboratory analyses (lipemia)
• For hydrophilic beta-blockers (e.g., atenolol, sotalol), the benefit of the lipid sink theory is questionable
• ILE does not replace HIET but rather complements it

Step 6: Further Escalation Measures

Glucagon:

• Classically described as an antidote for beta-blocker intoxication
• Acts via the glucagon receptor on the myocardium: Activation of adenylate cyclase independent of the β-receptor → cAMP increase → positive inotropy and chronotropy
• Dosing: 3–10 mg IV bolus, then 3–5 mg/h as infusion
• Limitations: Emetogenic (aspiration risk!), tachyphylaxis, limited availability in sufficient quantities, inconsistent clinical evidence
• HIET has largely replaced glucagon as the primary metabolic therapy

Phosphodiesterase III Inhibitors (Milrinone):

• Act via intracellular cAMP elevation independent of the β-receptor
• Milrinone: 50 µg/kg bolus, then 0.375–0.75 µg/kg/min
• Useful as rescue therapy in beta-blocker intoxication
• Caution: Vasodilation may aggravate hypotension

Pacing Therapy:

• Transcutaneous or transvenous pacing for symptomatic bradycardia
• Capture is frequently unattainable or hemodynamically ineffective in the setting of severe myocardial depression
• Nevertheless, initiate early, as pacing may become effective with partial response to pharmacological therapy

Methylene Blue:

• Described as a rescue option for vasoplegic shock
• Inhibits NO-mediated vasodilation
• 1–2 mg/kg IV over 15 minutes

Extracorporeal Circulatory Support (VA-ECMO):

• Last resort for treatment-refractory cardiogenic shock
• Bridges to elimination of the toxic substance
• Early contact with an ECMO center is essential – transporting an unstable patient carries significant risk
• Particularly in young patients with a reversible cause, prognosis under ECMO is good

Algorithm at a Glance

1. Secure the airway, monitoring, IV access (ideally central venous catheter)
2. Decontamination: Activated charcoal, whole bowel irrigation for extended-release preparations if indicated
3. Atropine 0.5–1 mg IV (repeat up to 3 mg)
4. Calcium IV (especially for CCB)
5. Start HIET: Insulin 1 IU/kg bolus, then 1–10 IU/kg/h; glucose in parallel
6. Catecholamines: Norepinephrine ± epinephrine, vasopressin if needed
7. Lipid emulsion infusion for lipophilic substances
8. Glucagon or milrinone as rescue
9. Pacing for bradycardia
10. VA-ECMO for treatment-refractory shock – consider early and contact an ECMO center

Key Pitfalls

• Extended-release preparations: Symptom deterioration can occur hours after ingestion. Minimum monitoring duration is 24 hours; longer for extended-release formulations.
• Combined intoxication: Simultaneous ingestion of beta-blockers and CCBs potentiates toxicity disproportionately.
• Sotalol: Requires special attention regarding QT prolongation and Torsades de Pointes beyond standard beta-blocker management. Have magnesium (2 g IV) and overdrive pacing ready.
• Propranolol: QRS widening responds to sodium bicarbonate (1–2 mEq/kg IV) – analogous to sodium channel blockade by tricyclic antidepressants.
• Hypoglycemia: Regular blood glucose checks during HIET are mandatory. At the same time, paradoxical hyperglycemia may be present in CCB intoxication and is managed by HIET – insulin dose reduction is not indicated in this case.

Summary of Key Therapeutic Points

• HIET is the central metabolic therapy and should be initiated early in any hemodynamically significant beta-blocker or CCB intoxication.
• IV calcium is an important first-line component, especially in CCB poisoning.
• Catecholamines are frequently required in supramaximal doses – titrate dose escalation based on effect.
• Lipid emulsion infusion is a useful adjunct for lipophilic substances but does not replace HIET.
• VA-ECMO must be considered early as a rescue option before irreversible organ damage occurs.
• Extended-release preparations require prolonged monitoring and repeated decontamination.

Practical Training

Managing beta-blocker and calcium channel blocker intoxications requires rapid, structured decision-making under time pressure – from recognizing the poisoning pattern to correct HIET dosing to escalation to VA-ECMO. In the ACLS course by Simulation Tirol, you train these critical scenarios in realistic simulation environments. You practice the structured management of treatment-refractory bradycardia, the coordinated use of multiple antidote strategies, and team communication in complex emergency situations. Hands-on experience with the simulator builds the confidence and competence that make the difference in real-life outcomes.